Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 69 Neoplasms 21 Breast Neoplasms 21 Fallopian Tube Neoplasms 18 Prostatic Neoplasms 15 Neoplasm Metastasis 9 Pancreatic Neoplasms 8 Endometrial Neoplasms 8 Carcinoma, Ovarian Epithelial 8 Glioblastoma 7 Triple Negative Breast Neoplasms 6 Lung Neoplasms 5 Small Cell Lung Carcinoma 4 Glioma 4 Squamous Cell Carcinoma of Head and Neck 3 Recurrence 3 Mesothelioma 3 Melanoma 3 Head and Neck Neoplasms 3 Cystadenocarcinoma, Serous 3 Cholangiocarcinoma 3 Carcinoma 3 Uterine Neoplasms 2 Uterine Cervical Neoplasms 2 Urogenital Neoplasms 2 Stomach Neoplasms 2 Solid Tumor 2 Sarcoma 2 Prostatic Neoplasms, Castration-Resistant 2 Ovarian Diseases 2

Interventions

Gemcitabine 13 Albumin-Bound Paclitaxel 8 Taxes 6 130-nm albumin-bound paclitaxel 6 Fluorouracil 5 Oxaliplatin 4 dehydroftorafur 3 Radiotherapy, Intensity-Modulated 3 Radiotherapy 3 Leucovorin 3 Irinotecan 3 Losartan 2 Cisplatin 2 tocilizumab 1 selicrelumab 1 niraparib 1 irinotecan sucrosofate 1 indusatumab 1 folfirinox 1 durvalumab 1 cobimetinib 1 atezolizumab 1 X-Rays 1 Tiragolumab 1 Surgical Procedures, Operative 1 Standard of Care 1 Specimen Handling 1 S 1 (combination) 1 Resistance Training 1 Radiotherapy, Image-Guided 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Pancreatic Adenocarcinoma × niraparib × Clear all

NCT03404960 2025-10-10

Parpvax

University of Pennsylvania

Phase 1/2 Completed

104 enrolled 11 charts

Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡